Fintech▲ 50

CERo Therapeutics doses second patient in trial

Globenewswire·March 30, 2026 at 12:15 PM

CERo Therapeutics has successfully dosed the second patient in Cohort 2 of its Phase 1 trial for CER-1236. The trial is progressing with ongoing safety and pharmacologic evaluations. Plans are in place for expansion into Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF), indicating continued development and potential therapeutic applications for the drug candidate.

CERo Therapeutics doses second patient in trial

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing